The Restore Protections for Dialysis Patients Act amends section 1862(b)(1)(C) of the Social Security Act to prohibit group health plans from differentiating benefits or applying limitations that disparately affect individuals with end‑stage renal disease (ESRD), explicitly citing diagnosis of ESRD and the need for renal dialysis as prohibited grounds. The bill clarifies Congress’ intent to prevent private plans from treating dialysis differently than other covered medical services and to block strategies that shift primary payment responsibility for dialysis care onto Medicare.
Practically, the bill inserts broad anti‑discrimination language into the Medicare Secondary Payer framework while also saying that the statute does not force plans to include any particular dialysis provider in their networks. Enforcement is assigned to the Secretary and is tied to the nonconformance determination procedures in 42 C.F.R. part 411.
The change targets plan design choices—carve‑outs, dialysis‑specific exclusions, network structures, or other limits—that could push cost or care responsibility from private payers onto Medicare, and it raises compliance and enforcement questions for plans, regulators, and dialysis providers.
At a Glance
What It Does
The bill replaces clause (ii) of 42 U.S.C. 1395y(b)(1)(C) with language that forbids any differentiation in benefits or application of limitations that will disparately affect people with ESRD, explicitly referencing diagnosis of ESRD and need for renal dialysis. It also adds express text that the law does not require plans to include particular dialysis providers in their networks and directs the Secretary to use 42 C.F.R. part 411 nonconformance procedures in enforcement.
Who It Affects
Employer‑sponsored group health plans, issuers of commercial coverage, employers that sponsor self‑funded plans, dialysis providers, Medicare (as secondary payer), and patients with ESRD who have private coverage are directly affected. CMS and its enforcement apparatus will also have new interpretive and enforcement duties tied to MSPA rules.
Why It Matters
The bill tightens the federal prohibition against shifting dialysis costs to Medicare and narrows room for dialysis‑specific plan designs that could push patients onto the Medicare program. That changes the compliance calculus for plan design, network management, and provider contracting, and could influence insurer behavior and Medicare expenditures.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill changes the Medicare Secondary Payer (MSP) statute by inserting a broad, plain‑language ban on any benefit differentiation or limitations that single out people with end‑stage renal disease. In practice, that means a group health plan cannot lawfully design benefits—whether through coverage rules, cost‑sharing, prior authorization, or carve‑outs—that treat dialysis services worse than other medically necessary services if the practical effect is to disadvantage ESRD patients and shift primary payment responsibility toward Medicare.
The text calls out both a patient’s diagnosis of ESRD and the need for renal dialysis as examples of prohibited bases for differentiation. At the same time, the bill makes clear that it does not force plans to contract with any particular dialysis clinic or to meet a numeric quota of providers in their networks; plans retain their ordinary authority to assemble provider networks.
Enforcement is not left to private suits in the text; instead the Secretary of Health and Human Services is directed to enforce the new prohibition consistent with the nonconformance determination procedures already found in 42 C.F.R. part 411.For compliance officers, the practical implication is that plan design choices that specifically single out dialysis—for example, a dialysis carve‑out that offloads costs to Medicare, narrowly written dialysis benefits, or benefit tiers that create higher cost or access barriers exclusively for dialysis—could be vulnerable to enforcement under the MSP framework. For regulators, the statute increases the need to interpret what constitutes an impermissible ‘‘differentiation’’ or a limitation that will ‘‘disparately affect’’ ESRD patients and to do so within the administrative architecture of part 411.
The bill thereby creates a legal hook to challenge dialysis‑specific plan practices while preserving standard network selection authority for plans.
The Five Things You Need to Know
The bill amends 42 U.S.C. 1395y(b)(1)(C) by replacing clause (ii) with language that bars any benefit differentiation or limitation based on, or that disparately affects, individuals with ESRD — explicitly including diagnosis of ESRD and the need for renal dialysis.
The prohibition expressly covers limitations “including on network composition,” meaning dialysis‑specific network rules or arrangements that have a disparate impact on ESRD patients are targeted.
The statute adds a carve‑out: it does not require a group health plan to include any particular renal dialysis provider or a particular number of providers in its network, preserving normal network‑building discretion.
Enforcement is assigned to the Secretary and must be carried out “consistent with the nonconformance determination requirements set forth in part 411 of title 42, Code of Federal Regulations,” tying remedies and procedures to existing MSPA administrative rules.
The bill does not create an explicit private right of action or new monetary penalty scheme in the text; remedies and enforcement pathways are those available under the MSP framework as administered by HHS/CMS.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Provides the act’s short title: the "Restore Protections for Dialysis Patients Act." This is a naming provision only and has no substantive legal effect beyond identifying the legislation.
Purposes
Lists three congressional purposes: (1) restore MSPA protections so private plans do not discriminate against ESRD patients or treat dialysis worse than other services; (2) prohibit plans from shifting primary payment responsibility for dialysis to Medicare; and (3) clarify that singling out dialysis through coverage limitations is an inappropriate differentiation, while preserving a plan’s ability to select which dialysis providers to include in its network. The purpose language signals legislative intent that will inform statutory interpretation and administrative guidance.
Replace clause (ii): broad ban on ESRD‑targeted differentiations
Substitutes a new clause (ii) into 1862(b)(1)(C) that makes it unlawful for a plan to, on any basis (explicitly including ESRD diagnosis or need for dialysis), differentiate benefits between ESRD individuals and others or apply benefit limitations that will disparately affect ESRD individuals. The new wording is broad — ‘on any basis’ and ‘in any manner’ — and imports both disparate treatment and disparate impact concepts into MSP enforcement, which expands legal grounds beyond explicit exclusions to include the practical effects of plan design.
Clarification on provider inclusion and enforcement procedure
Adds two sentences after the new clause: first, it clarifies the statute does not mandate that group health plans include specific dialysis providers or a set number of such providers in their networks; second, it instructs the Secretary to enforce the provision consistent with the nonconformance determination rules in 42 C.F.R. part 411. The first sentence preserves standard network discretion; the second ties enforcement to existing MSP administrative mechanisms (notice, determination, and related recovery procedures) rather than creating a separate enforcement regime.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- People with ESRD who remain covered by employer‑sponsored or other group health plans — the bill shields them from dialysis‑specific benefit designs that would shift primary payment to Medicare or limit access.
- Dialysis patients seeking continuity of private coverage — reduced risk of coverage carve‑outs, higher cost‑sharing, or benefit definitions that effectively second‑class dialysis compared with other services.
- Dialysis providers that rely on private payers for reimbursement — the prohibition can reduce frequency of cost‑shifting to Medicare and support claims for primary payment by private plans.
Who Bears the Cost
- Group health plans and commercial insurers — they face constraints on dialysis‑specific benefit design and may incur higher costs if plans can no longer lawfully structure benefits in ways that push dialysis costs to Medicare.
- Employers that sponsor self‑insured plans — potential increases in premium or plan costs, plus administrative expense to review and redesign benefits to ensure compliance.
- CMS/HHS — the agency will need to interpret the statute, monitor plan practices under the MSP framework, and apply part 411 procedures more frequently, creating enforcement and administrative burdens.
Key Issues
The Core Tension
The bill pits two legitimate policy goals against each other: protecting a clinically vulnerable population from being carved out of private coverage or pushed onto Medicare, versus preserving insurers’ and employers’ ability to manage networks and control costs through targeted benefit design. The legislation tightens protections for ESRD patients but forces CMS and plans to reconcile access protections with the realities of network management and actuarial cost control.
The bill creates an expansive, effect‑based prohibition but leaves several consequential implementation questions open. First, the statute’s phrasing — banning differentiation “on any basis” or “in any manner” that disparately affects ESRD patients — imports an effects standard that will require CMS to develop tests for disparate impact in the MSP context.
Regulators will need to decide which plan features (e.g., benefit exclusions, higher cost‑sharing, prior authorization rules, network narrowness, reimbursement carve‑outs) trigger enforcement and how to measure disparate effect versus legitimate actuarial or cost‑control design.
Second, tying enforcement to 42 C.F.R. part 411 nonconformance procedures narrows the available playbook to the administrative apparatus already used for MSP disputes: notice, determination, and recovery processes. That choice limits remedies to administrative recovery and the MSP enforcement process rather than creating broad new statutory penalties or a private cause of action.
It also raises procedural questions about how quickly CMS can adjudicate systemic plan practices and whether courts will be invited to review agency interpretations. Finally, while the bill preserves plans’ ability to choose which providers to include, insurers may respond to the new constraint by adjusting other design levers or by avoiding enrolling people likely to develop ESRD — outcomes the statute does not directly address and that may shift costs or access in unforeseen ways.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.